-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Spruce Biosciences, Raises Price Target to $259

Benzinga·11/11/2025 13:55:14
Listen to the news
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and raises the price target from $254 to $259.